Icon (ICLR) Projected to Post Quarterly Earnings on Wednesday

Icon (NASDAQ:ICLR) is expected to release its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $3.32 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Icon Price Performance

Icon stock opened at $144.55 on Wednesday. The firm has a market capitalization of $11.67 billion, a P/E ratio of 19.56, a PEG ratio of 3.24 and a beta of 1.27. Icon has a 1 year low of $125.10 and a 1 year high of $211.00. The business has a 50-day moving average of $180.99 and a 200-day moving average of $176.59. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ICLR. Robert W. Baird set a $217.00 price objective on shares of Icon in a report on Friday, January 9th. Truist Financial reissued a “hold” rating and set a $222.00 price target (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Leerink Partners restated an “outperform” rating on shares of Icon in a research report on Monday, January 5th. Mizuho set a $216.00 price objective on Icon in a research note on Friday, January 9th. Finally, Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Six investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $200.60.

Hedge Funds Weigh In On Icon

Several hedge funds have recently made changes to their positions in ICLR. Johnson Financial Group Inc. acquired a new stake in shares of Icon in the third quarter valued at approximately $71,000. Quadrant Capital Group LLC bought a new position in Icon in the third quarter valued at $78,000. Geneos Wealth Management Inc. increased its stake in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after buying an additional 56 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after buying an additional 289 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Icon during the 3rd quarter worth about $207,000. 95.61% of the stock is owned by institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.